An observational study in COPD and Emphysema, sponsored by Gelb, Arthur F., M.D.. Completed at 1 site in United States. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2008-08-14.
Sponsored by Gelb, Arthur F., M.D. · Observational
To evaluate if tiotropium (Spiriva)induced bronchodilation of inspiratory capacity in patients with moderate to severe copd subjected to metronome paced hyperventilation induced dynamic hyperinflation is dependent upon the extent of underlying emphysema as determined by high resolution-thin section CT lung.
We will analyze post hoc, data that was previously published: Gelb AF et al.Chest 2006;131:690-695. We have shown that tiotropium increases resting inspiratory capacity thereby providing lung volume protection against metronome paced hyperventilation induced dynamic hyperinflation. End point will be to correlate increase in tiotropium induced FEV 1(L) and inspiratory capacity with extent of underlying emphysema as scored by lung CT ( Gelb AF et al:Chest 1996; 109: 353-359)in 29 patients with COPD. We will also correlate the decrease in inspiratory capacity following metronome paced hyperventilation induced dynamic hyperinflation with extent of lung CT scored emphysema.
187 studies on the registry are indexed under Pulmonary Emphysema; 19 are open to participants now.
This study's enrollment of 29 is below the median of 74 across 48 observational studies indexed under Pulmonary Emphysema.
Browse Pulmonary Emphysema studies →Gelb, Arthur F., M.D. is the lead sponsor of 7 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients with moderate to severe copd from tertiary care pulmonary clinic
Exclusion Criteria
patients with moderate to severe copd with varying extent of emphysema
Drug: tiotropium
18ug capsule daily for 30 days
Also known as: Spiriva
Correlate tiotropium induced increase in inspiratory capacity (IC)and FEV 1 with extent of emphysema as scored by lung CT.
Time frame: After 30 days and 1.5hr of tiotropium
Correlate decrease in IC and FEV 1 following dynamic hyperinflation with underlying emphysema.
Time frame: After 30 days and 1.5hr of tiotropium
This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gelb, Arthur F., M.D.